Microglial involvement in Alzheimer's disease (AD) pathology has emerged as a risk-
determining pathogenic event. While apolipoprotein E (APOE) is known to modify AD risk, it …

The blood–brain barrier (BBB) is a unique and selective feature of the central nervous
system's vasculature. BBB dysfunction has been observed as an early sign of Alzheimer's …

Diseases affecting the brain and spinal cord fall under the umbrella term “central nervous
system disease”. Most medications used to treat or prevent chronic diseases of the central …

Microglia have an innate immunity memory (IIM) with divergent functions in different animal
models of neurodegenerative diseases, including Alzheimer's disease (AD). AD is …

Accumulating evidences reveal that cellular cholesterol deficiency could trigger the onset of
Alzheimer's disease (AD). As a key regulator, 24-dehydrocholesterol reductase (DHCR24) …

Neuroinflammation, a major hallmark of Alzheimer's disease and several other neurological
and psychiatric disorders, is often associated with dysregulated cholesterol metabolism …

The main role of cholesteryl ester transfer protein (CETP) is the transfer of cholesteryl esters
and triglycerides between high-density lipoprotein (HDL) particles and triglyceride-rich …

The toxicology field is concerned with the impact of organophosphorus (OP) compounds on
human health. These compounds have been linked to an increased risk of neurological …

Alzheimer's disease is a progressive neurodegenerative disorder and the most common
cause of dementia that principally affects older adults. Pathogenic factors, such as oxidative …

Astrocytes, a type of glial cell in the central nervous system (CNS), adopt diverse states in
response to injury that are influenced by their location relative to the insult. Here, we …